MCID: INV004
MIFTS: 30

Invasive Bladder Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Invasive Bladder Transitional Cell Carcinoma

MalaCards integrated aliases for Invasive Bladder Transitional Cell Carcinoma:

Name: Invasive Bladder Transitional Cell Carcinoma 12 15
Infiltrating Bladder Urothelial Carcinoma 71
Invasive Bladder Urothelial Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6477
NCIt 49 C27885
UMLS 71 C1334281

Summaries for Invasive Bladder Transitional Cell Carcinoma

MalaCards based summary : Invasive Bladder Transitional Cell Carcinoma, also known as infiltrating bladder urothelial carcinoma, is related to transitional cell carcinoma and non-invasive bladder urothelial carcinoma, and has symptoms including dysuria An important gene associated with Invasive Bladder Transitional Cell Carcinoma is RBX1 (Ring-Box 1), and among its related pathways/superpathways are Pathways in cancer and TGF-beta Signaling Pathway (WikiPathways). The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate.

Related Diseases for Invasive Bladder Transitional Cell Carcinoma

Diseases related to Invasive Bladder Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 30.6 UPK3A TP53 CDKN1A
2 non-invasive bladder urothelial carcinoma 12.7
3 splenic diffuse red pulp small b-cell lymphoma 10.3 TP53 NOTCH1
4 actinic cheilitis 10.3 TP53 CDKN1A
5 suppressor of tumorigenicity 3 10.3 TP53 CDKN1A
6 bladder transitional cell papilloma 10.3 TP53 CDKN1A
7 oral leukoplakia 10.3 TP53 IFI27
8 bladder cancer 10.2
9 uterine adnexa cancer 10.2 TP53 NOTCH1
10 bone squamous cell carcinoma 10.2 TP53 NOTCH1
11 lip cancer 10.2 TP53 CDKN1A
12 urethra transitional cell carcinoma 10.1 UPK3A TP53
13 bladder urothelial carcinoma 10.1
14 papillary transitional carcinoma 10.1 UPK3A TP53
15 non-invasive bladder papillary urothelial neoplasm 10.1 UPK3A TP53
16 glandular cystitis 10.1 UPK3A TP53
17 coronary restenosis 10.1 IFI27 CDKN1A
18 urinary tract papillary transitional cell benign neoplasm 10.1 UPK3A TP53
19 bladder papillary transitional cell neoplasm 10.1 UPK3A TP53
20 skin papilloma 10.1 TP53 CDKN1A
21 myxofibrosarcoma 10.1 TP53 IFI27 CDKN1A
22 bladder clear cell adenocarcinoma 10.1 UPK3A TP53
23 prostate cancer 10.0
24 neurogenic bladder 10.0
25 acute cystitis 10.0
26 rare tumor 10.0
27 tongue carcinoma 10.0 TP53 NOTCH1 CDKN1A
28 pancreatic adenocarcinoma 10.0
29 richter's syndrome 10.0 TP53 NOTCH1
30 suppression of tumorigenicity 12 9.9 TP53 NOTCH1 CDKN1A
31 kidney cancer 9.9 TP53 RBX1 MIR532 CDKN1A
32 mantle cell lymphoma 9.8 TP53 NOTCH1 CDKN1A
33 myeloma, multiple 9.8 TP53 RBX1 NOTCH1 CDKN1A
34 t-cell acute lymphoblastic leukemia 9.6 TP53 NOTCH1 CDKN1A

Graphical network of the top 20 diseases related to Invasive Bladder Transitional Cell Carcinoma:



Diseases related to Invasive Bladder Transitional Cell Carcinoma

Symptoms & Phenotypes for Invasive Bladder Transitional Cell Carcinoma

UMLS symptoms related to Invasive Bladder Transitional Cell Carcinoma:


dysuria

Drugs & Therapeutics for Invasive Bladder Transitional Cell Carcinoma

Drugs for Invasive Bladder Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2 95058-81-4 60750
2
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
3
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
4
leucovorin Approved Phase 2 58-05-9 6006 143
5
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
6
Methotrexate Approved Phase 1, Phase 2 59-05-2, 1959-05-2 126941
7
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
8
Vinblastine Approved Phase 1, Phase 2 865-21-4 241903 13342
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
10
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
11 Immunoglobulins Phase 2
12 Immunologic Factors Phase 2
13 Antibodies Phase 2
14 Vitamin B Complex Phase 2
15 Antibodies, Monoclonal Phase 2
16 Folic Acid Antagonists Phase 2
17 Folate Phase 2
18 Vitamin B9 Phase 2
19 Antiviral Agents Phase 2
20 Immunosuppressive Agents Phase 2
21 Anti-Infective Agents Phase 2
22 Antimetabolites Phase 2
23
Liposomal doxorubicin Phase 1, Phase 2 31703
24
Altretamine Approved Phase 1 645-05-6 2123

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder Unknown status NCT01616875 Phase 2 Cabazitaxel + Cisplatin chemotherapy
2 Multicenter Phase II Study of Gemcitabine/Cisplatin (GC) Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) in the Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma Recruiting NCT04099589 Phase 2 Toripalimab
3 A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer Recruiting NCT03744793 Phase 2 Avelumab;Pemetrexed
4 A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations Recruiting NCT03609216 Phase 2 Gemcitabine Hydrochloride;Cisplatin
5 NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma Recruiting NCT03549715 Phase 1, Phase 2 Durvalumab;Tremelimumab;MVAC Protocol
6 A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy Withdrawn NCT03419130 Phase 2
7 A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers Recruiting NCT02767921 Phase 1
8 A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma Withdrawn NCT03430687 Phase 1
9 A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer Recruiting NCT01495676
10 Prospective Study of Bladder-Preservation Chemo-Radiotherapy (Partial Bladder Hypo-fractionated Radiotherapy) for Patients With Muscle-Invasive Bladder Cancer Withdrawn NCT02688348
11 Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) of the Bladder Wall for Thermal Ablation of Muscle Invasive Cells of Bladder Tumors: Corroborating With Robot-Assisted Radical Cystectomy Withdrawn NCT03238664
12 Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy Withdrawn NCT02944357 Cisplatin;Gemcitabine Hydrochloride

Search NIH Clinical Center for Invasive Bladder Transitional Cell Carcinoma

Genetic Tests for Invasive Bladder Transitional Cell Carcinoma

Anatomical Context for Invasive Bladder Transitional Cell Carcinoma

MalaCards organs/tissues related to Invasive Bladder Transitional Cell Carcinoma:

40
Prostate

Publications for Invasive Bladder Transitional Cell Carcinoma

Articles related to Invasive Bladder Transitional Cell Carcinoma:

(show all 41)
# Title Authors PMID Year
1
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. 61
31493109 2020
2
Identifying Potential Prognostic Markers for Muscle-Invasive Bladder Urothelial Carcinoma by Weighted Gene Co-Expression Network Analysis. 61
31011911 2020
3
Moesin (MSN) as a Novel Proteome-Based Diagnostic Marker for Early Detection of Invasive Bladder Urothelial Carcinoma in Liquid-Based Cytology. 61
32326232 2020
4
The Landscape of Long Non-Coding RNA Dysregulation and Clinical Relevance in Muscle Invasive Bladder Urothelial Carcinoma. 61
31810243 2019
5
Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. 61
30775255 2019
6
[Recurrent invasive bladder urothelial carcinoma treated by cystectomy with substitutive ileal enterocystoplasty: case report]. 61
31565144 2019
7
A Novel Biomarker Based on miRNA to Predict the Prognosis of Muscle-Invasive Bladder Urothelial Carcinoma. 61
31885571 2019
8
IL‑23 concentration‑dependently regulates T24 cell proliferation, migration and invasion and is associated with prognosis in patients with bladder cancer. 61
30542702 2018
9
Clinical experience of MRI in two dogs with muscle-invasive transitional cell carcinoma of the urinary bladder. 61
27149892 2016
10
Relevance of prostate cancer in patients with synchronous invasive bladder urothelial carcinoma: a monocentric retrospective analysis. 61
25847902 2015
11
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. 61
26046361 2015
12
Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. 61
24333243 2014
13
Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. 61
24196429 2014
14
Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. 61
23994370 2014
15
Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. 61
23609182 2013
16
Abnormal expression of multiple proteins predicts cancer-specific mortality in patients with high-grade non-muscle-invasive bladder cancer treated with transurethral resection. 61
24649194 2013
17
Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma. 61
23479173 2013
18
Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence. 61
23667514 2013
19
Advanced transitional cell carcinoma of the bladder in a 16-year-old girl with Hinman syndrome. 61
22743257 2012
20
Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. 61
23587365 2012
21
[Expression analysis of NOTCH1/HES1/PTEN signaling pathway in invasive bladder transitional cell carcinoma]. 61
22781569 2012
22
Efficacy of instillations with chemotherapy or immunotherapy following endoscopic resection for upper tract urothelial carcinoma. 61
22149433 2012
23
Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma. 61
21516473 2011
24
Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray. 61
21251473 2011
25
Proteomics research on muscle-invasive bladder transitional cell carcinoma. 61
21645413 2011
26
Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma. 61
21449971 2011
27
[Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence]. 61
21419519 2011
28
Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. 61
20939013 2010
29
D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. 61
20174823 2010
30
Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. 61
19934319 2009
31
Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma. 61
19363744 2009
32
Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. 61
18499162 2008
33
Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease. 61
18372011 2008
34
[Place of laparoscopic radical cystectomy in the treatment of invasive bladder urothelial carcinoma]. 61
18472066 2008
35
Behavior of urothelial carcinoma with respect to anatomical location. 61
17437794 2007
36
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. 61
17222615 2007
37
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. 61
17011058 2006
38
[Radical cystectomy with sparing partial prostate for invasive bladder cancer]. 61
14558952 2003
39
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. 61
11696726 2001
40
The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M-VEC chemotherapy. 61
10571638 1999
41
Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital with cancer-centre status. 61
10233566 1999

Variations for Invasive Bladder Transitional Cell Carcinoma

Expression for Invasive Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Invasive Bladder Transitional Cell Carcinoma.

Pathways for Invasive Bladder Transitional Cell Carcinoma

GO Terms for Invasive Bladder Transitional Cell Carcinoma

Biological processes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 9.65 TP53 CSNK2A3 CDKN1A
2 cell cycle arrest GO:0007050 9.61 TP53 NOTCH1 CDKN1A
3 intrinsic apoptotic signaling pathway GO:0097193 9.56 TP53 CDKN1A
4 positive regulation of reactive oxygen species metabolic process GO:2000379 9.55 TP53 CDKN1A
5 cellular response to gamma radiation GO:0071480 9.54 TP53 CDKN1A
6 neuron fate commitment GO:0048663 9.52 ZNF521 NOTCH1
7 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.51 TP53 CDKN1A
8 tissue regeneration GO:0042246 9.49 NOTCH1 CDKN1A
9 response to X-ray GO:0010165 9.46 TP53 CDKN1A
10 heart development GO:0007507 9.46 TP53 PDLIM3 NOTCH1 CDKN1A
11 mitotic cell cycle arrest GO:0071850 9.4 TP53 CDKN1A
12 cardiac septum morphogenesis GO:0060411 9.37 TP53 NOTCH1
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 TP53 CDKN1A
14 replicative senescence GO:0090399 9.26 TP53 CDKN1A
15 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 8.96 TP53 NOTCH1
16 signal transduction by p53 class mediator GO:0072331 8.62 TP53 CDKN1A

Sources for Invasive Bladder Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....